The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence worldwide in the 21st century while its accurate etiology remains unclear. In the past decade, gut microbiota dysbiosis has consistently been associated with IBD. Although many IBDassociated dysbiosis have not b...

Full description

Saved in:
Bibliographic Details
Published inProtein & cell Vol. 12; no. 5; pp. 331 - 345
Main Authors Liu, Sheng, Zhao, Wenjing, Lan, Ping, Mou, Xiangyu
Format Journal Article
LanguageEnglish
Published Beijing Higher Education Press 01.05.2021
Springer Nature B.V
Oxford University Press
Subjects
Biochemistry
Biomedical and Life Sciences
Cell Biology
Developmental Biology
Disease
Dysbacteriosis
dysbiosis
Dysbiosis - microbiology
Dysbiosis - therapy
Etiology
Gastrointestinal Microbiome
Human Genetics
Humans
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory Bowel Diseases - microbiology
Inflammatory Bowel Diseases - therapy
Intestinal microflora
Intestine
Life Sciences
microbiome
Microbiomes
Microbiota
Models, Biological
Pathogenesis
Protein Science
Review
Reviews
Stem Cells
therapy
pathogenesis
microbiome
therapy
inflammatory bowel disease
etiology
dysbiosis
Online AccessGet full text

Cover

More Information
Summary:Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence worldwide in the 21st century while its accurate etiology remains unclear. In the past decade, gut microbiota dysbiosis has consistently been associated with IBD. Although many IBDassociated dysbiosis have not been proven to be a cause or an effect of IBD, it is often hypothesized that at least some of alteration in microbiome is protective or causative. In this article, we selectively reviewed the hypothesis supported by both association studies in human and pathogenesis studies in biological models. Specifically, we reviewed the potential protective bacterial pathways and species against IBD, as well as the potential causative bacterial pathways and species of IBD. We also reviewed the potential roles of some members of mycobiome and virome in IBD. Lastly, we covered the current status of therapeutic approaches targeting microbiome, which is a promising strategy to alleviate and cure this inflammatory disease.
Bibliography:pathogenesis
therapy
Document accepted on :2020-05-30
Document received on :2020-02-10
microbiome
inflammatory bowel disease
etiology
dysbiosis
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1674-800X
1674-8018
DOI:10.1007/s13238-020-00745-3